# US 2022/0033508 A1 · Anti-il13r alpha2 antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033508 A1
- Document ID: US20220033508A1
- Status: Published application
- Kind: A1
- Application number: 17/389,582
- Filed: 2021-07-30
- Published: 2022-02-03
- Earliest claimed: 2020-07-31
- Assignees: Adc Therapeutics SA
- Applicants: Adc Therapeutics SA
- Inventors: Patricius Hendrikus Cornelis Van Berkel; Francois Bertelli
- Web page: https://patentgrep.com/patent/US20220033508A1

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61K 47/6801: {Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent}
- A61P 35/00: Antineoplastic agents
- C07K 14/7155: {for interleukins [IL]}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/55: Fab or Fab'
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure relates to antibodies that specifically bind to the Interleukin-13 receptor subunit alpha-2 (IL13Rα2) protein, and associated uses and methods for production.

## Claims

### Claim 1

An antibody that binds to Interleukin-13 receptor subunit alpha-2 (IL13Rα2), which comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3.

### Claim 2 (depends on 1)

The antibody according to claim 1, wherein the antibody further comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4.

### Claim 3 (depends on 1)

The antibody according to claim 1, wherein the antibody binds IL13Rα2 with an affinity (KD) no greater than 5×10−10 M.

### Claim 4 (depends on 1)

The antibody according to claim 1, wherein the antibody competitively inhibits the binding to IL13Rα2 of an antibody comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 1 and a light chain variable region having the amino acid sequence of SEQ ID NO: 2.

### Claim 5 (depends on 1)

The antibody according to claim 1, wherein the antibody binds IL13Rα2 with higher affinity (KD) than an antibody comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 1 and a light chain variable region having the amino acid sequence of SEQ ID NO: 2.

### Claim 6 (depends on 1)

The antibody according to claim 1, wherein the antibody has immunogenicity in a human subject that is lower than that of an antibody comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 1 and a light chain variable region having the amino acid sequence of SEQ ID NO: 2.

### Claim 7 (depends on 1)

The antibody according to claim 1, wherein the antibody has improved stability properties as compared to an antibody comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 1 and a light chain variable region having the amino acid sequence of SEQ ID NO: 2.

### Claim 8 (depends on 1)

The antibody according to claim 1, wherein the antibody comprises a constant region of isotype IgG1, IgG2, IgG3 or IgG4, or a mutated IgG constant region.

### Claim 9 (depends on 8)

The antibody of claim 8, wherein the constant region is human.

### Claim 10 (depends on 1)

The antibody according to claim 1, wherein the antibody is a Fab, a Fab′, a F(ab′)2, or an scFv.

### Claim 11 (depends on 1)

An antibody drug conjugate comprising the antibody according to claim 1 conjugated to a drug moiety.

### Claim 12 (depends on 11)

The antibody drug conjugate of claim 11, wherein the drug moiety comprises a pyrollobenzodiazepine dimer.

### Claim 13 (depends on 1)

A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable diluent, carrier, or excipient.

### Claim 14 (depends on 1)

A method of treating cancer in a subject, comprising administering the antibody of claim 1 to a subject in need thereof.

### Claim 15 (depends on 11)

A method of treating cancer in a subject, comprising administering the antibody drug conjugate of claim 11 to a subject in need thereof.

### Claim 16 (depends on 13)

A method of treating cancer in a subject, comprising administering the pharmaceutical composition of claim 13 to a subject in need thereof.

### Claim 17 (depends on 1)

A polynucleotide encoding an antibody according to claim 1.

### Claim 18 (depends on 17)

A vector comprising the polynucleotide of claim 17.

### Claim 19 (depends on 18)

A host cell comprising the vector according to claim 18.

### Claim 20 (depends on 11)

A pharmaceutical composition comprising the antibody drug conjugate of claim 11 and a pharmaceutically acceptable diluent, carrier, or excipient.

### Claim 21 (depends on 18)

The vector of claim 18, which is an expression vector.

### Claim 22 (depends on 19)

The host cell of claim 19, which is prokaryotic, eukaryotic, or mammalian.